This fact sheet is for men who are about to start, or are already taking, the hormone therapy drug degarelix to control their prostate cancer. It explains how the drug is taken, why it is used and what side effects it may cause.

Note: This publication is no longer updated. For current information about degarelix, please read our Hormone therapy fact sheet.

References  

Updated: Nov 2013 | Due for Review: Nov 2015

  • Alibhai SMH, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit. Rev. Oncol. Hematol. 2006 Dec;60(3):201–15
  • Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 2007 Jan;177(1):17–24
  • Ferring Pharmaceuticals March 2013. Firmagon 120mg Injection - Summary of Product Characteristics (SPC) - (eMC) [Internet]. [cited 2013 Jun 21]. Available from: http://www.medicines.org.uk
  • Ferring Pharmaceuticals March 2013. Firmagon 80mg Injection - Summary of Product Characteristics (SPC) - (eMC) [Internet]. [cited 2013 Jun 21]. Available from: http://www.medicines.org.uk
  • Keogh JWL & MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review. Journal of pain and symptom management. 2012;43(1):93-110
  • Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson B-E, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. Bju Int. 2008 Dec;102(11):1531–8
  • NICE. CG58 Prostate cancer: NICE guidance [Internet]. [cited 2013 Jan 9]. Available from: http://publications.nice.org.uk/prostate-cancer-cg58
    Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. Jama J. Am. Med. Assoc. 2005 Jul 13;294(2):238–44
  • Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):7–15
  • Smith MR, Klotz L, Persson B-E, et al. Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer. J Urol. 2010;184(6):2313–2319
  • Smith MR, Klotz L, van der Meulen E et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. Urol. 2011;186(5):1835-4Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin. Ther. 2009;31 Pt 2:2312–31
  • Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin. Ther. 2009;31 Pt 2:2312–31

About this publication  

This fact sheet is for men who are about to start, or are already taking, the hormone therapy drug degarelix to control their prostate cancer. It explains how the drug is taken, why it is used and what side effects it may cause.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.